More than 25 years after its discovery, the post-transcriptional gene regulation mechanism
termed RNAi is now transforming pharmaceutical development, proved by the recent FDA …

The introduction of the in vitro evolution method known as SELEX (systematic evolution of
ligands by exponential enrichment) more than 30 years ago led to the conception of …

Small interfering RNA (siRNA) delivery by nanocarriers has been identified as a promising
strategy in the study and treatment of cancer. Short nucleotide sequences are synthesized …

Functional nucleic acid (NA)-based drugs have a broad range of applications since they
allow the alteration and control of gene/protein expression patterns in cells. In principle …

Nucleic acid aptamers, often termed'chemical antibodies', are functionally comparable to
traditional antibodies, but offer several advantages, including their relatively small physical …

With the recent FDA approval of the first siRNA‐derived therapeutic, RNA interference
(RNAi)‐mediated gene therapy is undergoing a transition from research to the clinical …

siRNA is a promising therapeutic solution to address gene overexpression or mutations as a
post-transcriptional gene regulation process for several pathological conditions such as viral …

Aptamers are a class of small nucleic acid ligands that are composed of RNA or single-
stranded DNA oligonucleotides and have high specificity and affinity for their targets. Similar …

Nucleic acid aptamers can be selected from pools of random-sequence oligonucleotides to
bind a wide range of biomedically relevant proteins with affinities and specificities that are …

Recently, aptamers have attracted the attention of many scientists, because they not only
have all of the advantages of antibodies, but also have unique merits, such as thermal …